Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosamprenavir in Pediatric HIV
NCT00071760Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2003
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of fosamprenavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Primary endpoints: Plasma Amprenavir (APV) AUC (0-tau) at Week 48, Plasma APV Cmax at Week 48 and 4 more. Started Oct 2003; status: completed.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00071760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00071760.